Muta M - Search Results

1

Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer.

Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H, Matsushima K. Ueno T, et al. Among authors: muta m. Clin Cancer Res. 2000 Aug;6(8):3282-9. Clin Cancer Res. 2000. PMID: 10955814

2

Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer.

Toi M, Bando H, Ogawa T, Muta M, Hornig C, Weich HA. Toi M, et al. Among authors: muta m. Int J Cancer. 2002 Mar 1;98(1):14-8. doi: 10.1002/ijc.10121. Int J Cancer. 2002. PMID: 11857378

3

Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread.

Bando H, Matsumoto G, Bando M, Muta M, Ogawa T, Funata N, Nishihira J, Koike M, Toi M. Bando H, et al. Among authors: muta m. Jpn J Cancer Res. 2002 Apr;93(4):389-96. doi: 10.1111/j.1349-7006.2002.tb01269.x. Jpn J Cancer Res. 2002. PMID: 11985788 Free PMC article.

4

Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.

Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M, Umezawa K. Matsumoto G, et al. Among authors: muta m. Clin Cancer Res. 2005 Feb 1;11(3):1287-93. Clin Cancer Res. 2005. PMID: 15709200

5

Mechanical analysis of tumor growth regression by the cyclooxygenase-2 inhibitor, DFU, in a Walker256 rat tumor model: importance of monocyte chemoattractant protein-1 modulation.

Muta M, Matsumoto G, Nakashima E, Toi M. Muta M, et al. Clin Cancer Res. 2006 Jan 1;12(1):264-72. doi: 10.1158/1078-0432.CCR-05-1052. Clin Cancer Res. 2006. PMID: 16397051

6

Significance of membrane type 1 matrix metalloproteinase expression in breast cancer.

Ishigaki S, Toi M, Ueno T, Matsumoto H, Muta M, Koike M, Seiki M. Ishigaki S, et al. Among authors: muta m. Jpn J Cancer Res. 1999 May;90(5):516-22. doi: 10.1111/j.1349-7006.1999.tb00778.x. Jpn J Cancer Res. 1999. PMID: 10391091 Free PMC article. Clinical Trial.

7

A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients.

Suzuki E, Niwa R, Saji S, Muta M, Hirose M, Iida S, Shiotsu Y, Satoh M, Shitara K, Kondo M, Toi M. Suzuki E, et al. Among authors: muta m. Clin Cancer Res. 2007 Mar 15;13(6):1875-82. doi: 10.1158/1078-0432.CCR-06-1335. Clin Cancer Res. 2007. PMID: 17363544

8

Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer.

Toi M, Bando H, Horiguchi S, Takada M, Kataoka A, Ueno T, Saji S, Muta M, Funata N, Ohno S. Toi M, et al. Among authors: muta m. Br J Cancer. 2004 Jun 14;90(12):2338-43. doi: 10.1038/sj.bjc.6601845. Br J Cancer. 2004. PMID: 15150550 Free PMC article. Clinical Trial.

9

DFU, a selective COX-2 inhibitor, suppresses MCF-7 xenograft tumor growth in mice.

Matsumoto G, Rahman MA, Muta M, Nakamura T, Bando H, Saji S, Tsuruta K, Okamoto A, Toi M. Matsumoto G, et al. Among authors: muta m. Oncol Rep. 2004 Aug;12(2):281-5. Oncol Rep. 2004. PMID: 15254689

10

Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma.

Suzuki A, Toi M, Yamamoto Y, Saji S, Muta M, Tominaga T. Suzuki A, et al. Among authors: muta m. Jpn J Cancer Res. 1998 Feb;89(2):221-7. doi: 10.1111/j.1349-7006.1998.tb00552.x. Jpn J Cancer Res. 1998. PMID: 9548451 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49 results

Search Page

Filters